Ronald E Kates
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ronald E Kates has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Hofmann
West German Study Group, Ludwig-Weber-Str, 15b, 41061 Moenchengladbach, Germany.
1 shared publication - Nadia Harbeck
Breast Center, Department of Obstetrics and Gynecology, Comprehensive Cancer Center (CCC) Munich, University of Munich, Munich, Germany
1 shared publication - Oleg Gluz
West German Study Group Moenchengladbach Germany
1 shared publication - Peter Staib
Department of Hematology and Oncology, St Antonius Hospital Eschweiler, Eschweiler, Germany
1 shared publication - Timo Schinkoethe
Institute for Innovation and Medicine, Caramanicostr. 9A, 85551 Munich, Kirchheim, Germany
1 shared publication - Ulrike Nitz
West German Study Group (WSG), Moenchengladbach, Germany
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 261
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial and continuous improvement of outcome has been achieved over the past decades. Response to therapy is currently not considered in the decision-making procedure.
- 1 January 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 261
Open AccessWSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial and continuous improvement of outcome has been achieved over the past decades. Response to therapy is currently not considered in the decision-making procedure.